Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting Nonsense Mutations in Diseases with Translational Read-Through-Inducing Drugs (TRIDs).

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy - 1 Apr 2016

Nagel-Wolfrum Kerstin, Möller Fabian, Penner Inessa, Baasov Timor, Wolfrum Uwe

Abstract excerpt

In recent years, remarkable advances in the ability to diagnose genetic disorders have been made. The identification of disease-causing genes allows the development of gene-specific therapies with the ultimate goal to develop personalized medicines for each patient according to their own specific genetic defect. In-depth genotyping of many different genes has revealed that ~12% of inherited genetic disorders are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenosine and Purinergic Signaling
Share to Codon, Nonsense

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CRISPR and Genetic Engineering

Share to Genetic Diseases, Inborn

Share to Genetic Therapy

Share to Genotype

Share to Pharmaceutical Preparations

Share to RNA, Messenger

Source

Identifiers

PMID: 26886021
DOI: 10.1007/s40259-016-0157-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting Nonsense Mutations in Diseases with Translational Read-Through-Inducing Drugs (TRIDs).PMID 26886021Read ↗

Readthrough compounds for nonsense mutations: bridging the translational gap.Semantic proximity Read ↗

Suppression of Nonsense Mutations by New Emerging Technologies.Semantic proximity Read ↗

Genome-scale quantification and prediction of pathogenic stop codon readthrough by small moleculesSemantic proximity Read ↗

Introducing sense into nonsense in treatments of human genetic diseases.Semantic proximity Read ↗

Nonsense Suppression as an Approach to Treat Lysosomal Storage DiseasesSemantic proximity Read ↗

Readthrough Activators and Nonsense-Mediated mRNA Decay Inhibitor Molecules: Real Potential in Many Genetic Diseases Harboring Premature Termination CodonsSemantic proximity Read ↗

Readthrough approach by NV translational readthrough inducing drugs (TRIDs): a study of the possible off-target effects on natural termination codons (NTCs) on TP53 and housekeeping genes expression.Semantic proximity Read ↗

Therapeutic suppression of premature termination codons: mechanisms and clinical considerations (review).Semantic proximity Read ↗

Therapeutic Suppression of Nonsense Mutation: An Emerging Target in Multiple Diseases and Thrombotic Disorders.Semantic proximity Read ↗

PTC124 targets genetic disorders caused by nonsense mutations.Semantic proximity Read ↗

Therapeutic promise of engineered nonsense suppressor tRNAs.Semantic proximity Read ↗

Read-through strategies for suppression of nonsense mutations in Duchenne/ Becker muscular dystrophy: aminoglycosides and ataluren (PTC124).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.